- $82.72m
- $52.50m
- $13.56m
Brief: Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
Hyperfine Inc reports results for the quarter ended in December - Earnings Summary
Hyperfine Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Hyperfine Announces Collaboration With Athletic Heart To Provide Brain Health Imaging
Brief: Hyperfine Inc Files For Debt Shelf Of Upto $150 Million - SEC Filing
Brief: Hyperfine Receives FDA Clearance For Updated AI-Powered Software
Brief: Hyperfine, Inc. Q2 sales USD 3.381 million
Brief: Hyperfine Announces Promotion Of Tom Teisseyre To Chief Operating Officer
Brief: Hyperfine Inc Says Expansion Of Clinical Research To Study Neurological Effects Of Early Childhood Malnutrition In Low, Middle-Income Countries
U.S. RESEARCH ROUNDUP-Allakos, Virtu Financial, Walt Disney
Brief: Hyperfine, Inc. Reports First Quarter 2023 Financial Results
Brief: Hyperfine Inc Reports Fourth Quarter Financial Results
Brief: Hyperfine Inc - Does Not Hold Any Deposits Or Securities Or Maintain Any Accounts At Silicon Valley Bank
Brief: Hyperfine, Inc. Receives FDA Clearance For Updated Software To Further Improve Diffusion-Weighted Imaging
Brief: Hyperfine Announces Brett Hale As Chief Administrative Officer & CFO
Brief: Hyperfine Inc Files For Offering Of 41.8 Million Share Of Class A Common Stock And 15.1 Million Shares Of Class B Common Stock By Selling Securityholders - Filing
Brief: Hyperfine Says On Dec 6, 2022, Co Committed To Organizational Restructuring Designed To Decrease Costs, Create Streamlined Organization To Support Business
Brief: Hyperfine Inc- On December 6, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq - Filing
Brief: Hyperfine Reports Third Quarter 2022 Financial Results